IRAK-targeted therapies that have matriculated to early phase trials are yielding promising
preliminary results. However, studies of IRAK kinase signaling continue to defy conventional …

Opinion statement The treatment of myelodysplastic syndromes (MDS) begins with risk
stratification using a validated tool such as the International Prognostic Scoring System …

Small molecule potent IRAK4 inhibitors from a novel bicyclic heterocycle class were
designed and synthesized based on hits identified from Aurigene's compound library. The …

Several studies have identified mutations in the MYD88L265P gene as a key driver mutation
in several B-cell lymphomas. B-cell lymphomas that harbor the MYD88L265P mutation form …

Approval of new agents to treat higher risk (HR) myelodysplastic syndrome (MDS) has
stalled since the approval of DNA methyltransferase inhibitors (DNMTi). In addition, the …

Hematopoietic stem cell aging, through the acquisition of somatic mutations, gives rise to
clonal hematopoiesis (CH). While a high prevalence of CH has been described in otherwise …

Pathogen-associated molecular patterns (PAMPs) like bacterial cell wall components and
viral nucleic acids are known ligands of innate inflammatory receptors that trigger multiple …

The myelodysplastic syndromes (MDS) are common myeloid malignancies. Mutations in
genes encoding different components of the spliceosome occur in more than half of all MDS …

The heterogeneous nature of myelodysplastic syndromes (MDS) demands a risk-adapted
therapeutic approach, and higher risk MDS, characterized by an increased risk of …

Splicing factors are frequently mutated in myelodysplastic syndromes (MDS) and acute
myeloid leukemia (AML). These mutations are presumed to contribute to oncogenic …